# Mohan Purushothaman

> Mohan Purushothaman is the co-founder, chairman, and CEO of Progentec Diagnostics, an Oklahoma City company building blood tests and digital tools that aim to predict autoimmune disease flares before they happen. He came to diagnostics by an unusual route: a Johns Hopkins Ph.D. focused on pharmaceutical pricing, a Harvard research fellowship, five years inside Roche, and a pricing-software practice he built and sold to Alliance Life Sciences. In 2014 he turned that commercial instinct toward lupus, partnering with the Oklahoma Medical Research Foundation, and in 2020 raised a $5M Series A led by Plains Venture Partners to bring the aiSLE DX flare-prediction platform and the LupusCorner patient community to market.

- **Role:** Co-founder, Chairman & CEO at Progentec Diagnostics, Inc.
- **Organizations:** Progentec Diagnostics, Inc., Alliance Life Sciences, Net Margins, Roche
- **Nationality:** United States
- **Education:** Ph.D., focus on Pharmaceutical Pricing, Johns Hopkins University, Research Fellow, Harvard University
- **Known for:** Co-founded Progentec Diagnostics and grew it into a recognized autoimmune-disease diagnostics and digital-health company, Raised a $5M Series A in January 2020 led by Plains Venture Partners, with backers including Stanford University, Mayo Clinic, OCA Ventures and NMC Health, Brought the aiSLE DX flare-prediction blood test to market, aiming to forecast lupus flares weeks in advance

## Career timeline

- **pre-2009** — Research Fellow at Harvard University; earned Ph.D. at Johns Hopkins focused on pharmaceutical pricing
- **~2009-2014** — Spent roughly five years at Roche leading life-cycle pricing and contracting strategy across many products
- **to 2014** — Built a pricing practice at Net Margins (acquired by Alliance Life Sciences); served as Global Practice Lead for Pricing and Market Access; developed an Enterprise Price Optimization software widely used by major pharma
- **2014** — Co-founded Progentec Diagnostics in Oklahoma City to commercialize autoimmune diagnostics, partnering with the Oklahoma Medical Research Foundation
- **2020** — Raised $5M Series A led by Plains Venture Partners; launched the aiSLE DX lupus flare-prediction and classification platform
- **present** — Serves as Chairman and CEO of Progentec Diagnostics

## Achievements

- Co-founded Progentec Diagnostics and grew it into a recognized autoimmune-disease diagnostics and digital-health company
- Raised a $5M Series A in January 2020 led by Plains Venture Partners, with backers including Stanford University, Mayo Clinic, OCA Ventures and NMC Health
- Brought the aiSLE DX flare-prediction blood test to market, aiming to forecast lupus flares weeks in advance
- Built the LupusCorner patient-engagement community and remote clinical-study capability
- Earlier, designed an Enterprise Price Optimization software adopted by many leading pharmaceutical companies

## Latest updates

- **2020-01** — Progentec closed a $5M Series A led by Plains Venture Partners and announced the rollout of its aiSLE DX flare-prediction and lupus-classification tests.

## Links

- Website: https://progentec.com
- LinkedIn: https://www.linkedin.com/in/mohanpurushothaman/

---

Profile page: https://yespress.io/mohan-purushothaman
Published by YesPress — https://yespress.io
Last updated: 2026-06-10